CryoPort/$CYRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CryoPort
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Ticker
$CYRX
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
1,098
ISIN
US2290503075
Website
CryoPort Metrics
BasicAdvanced
$373M
-
-$2.34
1.92
-
Price and volume
Market cap
$373M
Beta
1.92
52-week high
$9.78
52-week low
$4.58
Average daily volume
513K
Financial strength
Current ratio
5.556
Quick ratio
3.68
Long term debt to equity
56.215
Total debt to equity
60.848
Interest coverage (TTM)
-18.61%
Profitability
EBITDA (TTM)
-27.12
Gross margin (TTM)
44.46%
Net profit margin (TTM)
-46.46%
Operating margin (TTM)
-25.03%
Effective tax rate (TTM)
-1.30%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-4.84%
Return on equity (TTM)
-24.97%
Valuation
Price to revenue (TTM)
1.587
Price to book
1.03
Price to tangible book (TTM)
1.9
Price to free cash flow (TTM)
-9.7
Free cash flow yield (TTM)
-10.31%
Free cash flow per share (TTM)
-76.60%
Growth
Revenue change (TTM)
3.16%
Earnings per share change (TTM)
-5.50%
3-year revenue growth (CAGR)
1.56%
3-year earnings per share growth (CAGR)
-27.74%
What the Analysts think about CryoPort
Analyst ratings (Buy, Hold, Sell) for CryoPort stock.
Bulls say / Bears say
Cryoport's Life Sciences Services revenue increased by 17.3% year-over-year in Q1 2025, indicating strong growth in this segment. (aijourn.com)
The company supported 701 global clinical trials as of December 31, 2024, up from 675 the previous year, reflecting its expanding role in the biopharmaceutical industry. (ir.cryoportinc.com)
Cryoport held $261.7 million in cash, cash equivalents, and short-term investments as of December 31, 2024, providing a strong liquidity position to support future growth initiatives. (marketscreener.com)
Cryoport reported a net loss of $114.8 million for FY 2024, an increase from $99.6 million in the previous year, indicating ongoing profitability challenges. (marketscreener.com)
The Life Sciences Products segment experienced a revenue decline of 16.2% in FY 2024 compared to the previous year, suggesting potential issues in product demand or market competition. (ir.cryoportinc.com)
Cryoport's adjusted EBITDA was negative $15.1 million for FY 2024, compared to negative $8.3 million in FY 2023, reflecting deteriorating operational profitability. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
CryoPort Financial Performance
Revenues and expenses
CryoPort Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CryoPort stock?
CryoPort (CYRX) has a market cap of $373M as of July 18, 2025.
What is the P/E ratio for CryoPort stock?
The price to earnings (P/E) ratio for CryoPort (CYRX) stock is 0 as of July 18, 2025.
Does CryoPort stock pay dividends?
No, CryoPort (CYRX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next CryoPort dividend payment date?
CryoPort (CYRX) stock does not pay dividends to its shareholders.
What is the beta indicator for CryoPort?
CryoPort (CYRX) has a beta rating of 1.92. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.